Predictors	O
of	O
chronic	B-DS
kidney	I-DS
disease	I-DS
in	O
type	B-DS
1	I-DS
diabetes	I-DS
:	O
a	O
longitudinal	O
study	O
from	O
the	O
AMD	O
Annals	O
initiative	O

We	O
evaluated	O
2	O
,	O
656	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
and	O
preserved	O
renal	O
function	O
from	O
the	O
database	O
of	O
the	O
Italian	O
Association	O
of	O
Clinical	O
Diabetologists	O
network	O
to	O
identify	O
clinical	O
predictors	O
for	O
the	O
development	O
of	O
chronic	B-DS
kidney	I-DS
disease	I-DS
.	O

We	O
measured	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
),	O
urinary	O
albumin	B-GP
excretion	O
,	O
HbA1c	O
,	O
lipids	O
,	O
blood	O
pressure	O
.	O

Over	O
a	O
5	O
-	O
year	O
period	O
4	O
.	O
3	O
%	O
(	O
n	O
=	O
115	O
)	O
developed	O
reduced	O
eGFR	O
(<	O
60	O
ml	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
),	O
18	O
.	O
0	O
%	O
(	O
n	O
=	O
477	O
)	O
albuminuria	O
,	O
and	O
21	O
.	O
0	O
%	O
(	O
n	O
=	O
559	O
)	O
either	O
one	O
of	O
the	O
renal	O
endpoints	O
(	O
CKD	B-DS
).	O

Odds	O
ratios	O
for	O
eGFR	O
below	O
90	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
(	O
1	O
.	O
48	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
HbA1c	O
(	O
1	O
.	O
13	O
,	O
P	O
=	O
0	O
.	O
002	O
),	O
triglycerides	O
(	O
1	O
.	O
04	O
,	O
P	O
=	O
0	O
.	O
021	O
by	O
20	O
mg	O
/	O
dL	O
),	O
low	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
c	O
)	O
(	O
0	O
.	O
95	O
,	O
P	O
=	O
0	O
.	O
002	O
by	O
10	O
mg	O
/	O
dL	O
)	O
were	O
independently	O
related	O
to	O
the	O
onset	O
of	O
CKD	B-DS
.	O

Known	O
duration	O
of	O
diabetes	B-DS
(	O
1	O
.	O
15	O
,	O
P	O
=	O
0	O
.	O
014	O
by	O
10	O
years	O
),	O
HbA1c	O
(	O
1	O
.	O
16	O
,	O
P	O
=	O
0	O
.	O
001	O
),	O
triglycerides	O
(	O
1	O
.	O
05	O
,	O
P	O
=	O
0	O
.	O
005	O
by	O
20	O
mg	O
/	O
dL	O
),	O
LDL	O
-	O
c	O
(	O
0	O
.	O
95	O
,	O
P	O
=	O
0	O
.	O
003	O
by	O
10	O
mg	O
/	O
dL	O
),	O
antihypertensive	O
treatment	O
(	O
2	O
.	O
28	O
,	O
P	O
=	O
0	O
.	O
018	O
)	O
were	O
related	O
to	O
the	O
onset	O
of	O
albuminuria	O
while	O
age	O
and	O
presence	O
of	O
baseline	O
eGFR	O
values	O
between	O
90	O
and	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
,	O
independently	O
affected	O
the	O
developing	O
of	O
reduced	O
eGFR	O
(	O
OR	O
1	O
.	O
95	O
,	O
P	O
<	O
0	O
.	O
001	O
by	O
10	O
years	O
and	O
2	O
.	O
92	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
and	O
unfavorable	O
CV	O
risk	O
profile	O
are	O
at	O
high	O
risk	O
of	O
developing	O
CKD	B-DS
.	O

The	O
two	O
main	O
traits	O
of	O
CKD	B-DS
share	O
several	O
determinants	O
,	O
although	O
with	O
some	O
specificities	O
.	O

Introduction	O

Diabetes	B-DS
is	O
one	O
of	O
the	O
largest	O
health	O
emergencies	O
of	O
the	O
21st	O
century	O
.	O

The	O
International	O
Diabetes	B-DS
Federation	O
Diabetes	B-DS
Atlas	O
estimated	O
that	O
in	O
2015	O
,	O
there	O
were	O
415	O
million	O
patients	O
with	O
diabetes	B-DS
worldwide	O
and	O
by	O
2040	O
this	O
figure	O
will	O
rise	O
to	O
642	O
million	O
people	O
.	O

Type	B-DS
1	I-DS
diabetes	I-DS
is	O
less	O
common	O
,	O
accounting	O
for	O
7	O
–	O
12	O
%	O
of	O
the	O
total	O
cases	O
and	O
it	O
is	O
still	O
increasing	O
by	O
approximately	O
3	O
%	O
each	O
year	O
globally	O
,	O
particularly	O
among	O
children1	O
.	O

Long	O
-	O
term	O
complications	O
due	O
to	O
diabetes	B-DS
are	O
a	O
major	O
cause	O
of	O
disability	O
,	O
reduced	O
quality	O
of	O
life	O
and	O
premature	O
death2	O
.	O

Approximately	O
5	O
.	O
0	O
million	O
people	O
aged	O
between	O
20	O
and	O
79	O
years	O
died	O
from	O
diabetes	B-DS
in	O
2015	O
,	O
which	O
accounts	O
for	O
14	O
.	O
5	O
%	O
of	O
global	O
all	O
-	O
cause	O
mortality	O
among	O
people	O
in	O
this	O
age	O
group1	O
.	O

This	O
risk	O
excess	O
seems	O
to	O
be	O
essentially	O
driven	O
by	O
kidney	B-DS
disease3	I-DS
.	O

Chronic	B-DS
kidney	I-DS
disease	I-DS
(	O
CKD	B-DS
)	O
is	O
detected	O
clinically	O
by	O
screening	O
for	O
persistent	O
increased	O
urine	O
albumin	B-GP
excretion	O
and	O
for	O
a	O
decreased	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
)	O
4	O
.	O

Diabetes	B-DS
CKD	B-DS
is	O
the	O
leading	O
cause	O
of	O
end	B-DS
-	I-DS
stage	I-DS
renal	I-DS
disease	I-DS
in	O
the	O
Western	O
world5	O
and	O
it	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
cardiovascular	O
(	O
CV	O
)	O
events6	O
,	O
which	O
in	O
turn	O
remain	O
the	O
leading	O
cause	O
of	O
death	O
in	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus3	O
,	O
7	O
,	O
8	O
.	O

In	O
addition	O
to	O
genetic	O
determinants9	O
,	O
hyperglycemia	B-DS
,	O
dyslipidemia	B-DS
,	O
increased	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
smoking	O
are	O
known	O
to	O
be	O
risk	O
factors	O
for	O
the	O
onset	O
and	O
progression	O
of	O
diabetic	B-DS
renal	I-DS
damage10	I-DS
,	O
11	O
.	O

The	O
natural	O
history	O
of	O
diabetic	B-DS
nephropathy	I-DS
in	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
has	O
traditionally	O
been	O
associated	O
with	O
an	O
increase	O
in	O
urinary	O
albumin	B-GP
excretion	O
rate	O
(	O
AER	O
),	O
which	O
is	O
the	O
first	O
sign	O
of	O
renal	B-DS
damage	I-DS
and	O
may	O
foster	O
progression	O
to	O
macroalbuminuria	O
and	O
later	O
on	O
decrease	O
in	O
GFR12	O
.	O

More	O
recently	O
however	O
,	O
several	O
studies	O
have	O
provided	O
a	O
more	O
heterogeneous	O
picture	O
of	O
renal	O
phenotype	O
in	O
T1D	B-DS
patients	O
with	O
CKD	B-DS
,	O
with	O
a	O
significant	O
number	O
of	O
patients	O
progressing	O
towards	O
ESRD	B-DS
in	O
the	O
absence	O
of	O
albuminuria	O
.	O

Whether	O
renal	O
lesions	O
found	O
in	O
non	B-DS
albuminuric	I-DS
CKD	I-DS
are	O
specifically	O
due	O
to	O
diabetes	B-DS
or	O
may	O
in	O
part	O
recognize	O
different	O
pathogenetic	O
mechanisms	O
is	O
sometimes	O
difficult	O
to	O
ascertain	O
in	O
clinical	O
practice	O
as	O
renal	O
biopsies	O
are	O
not	O
routinely	O
performed	O
in	O
most	O
of	O
these	O
patients	O
.	O

We	O
retrospectively	O
analysed	O
a	O
large	O
cohort	O
of	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
and	O
normal	O
renal	O
function	O
at	O
baseline	O
,	O
to	O
evaluate	O
predictors	O
for	O
the	O
development	O
and	O
progression	O
of	O
depressed	O
kidney	O
function	O
+	O
/−	O
and	O
/	O
or	O
albuminuria	O
or	O
its	O
single	O
components	O
,	O
and	O
their	O
relationship	O
with	O
traditional	O
risk	O
factors	O
.	O

Results	O

Clinical	O
features	O
of	O
study	O
population	O
at	O
baseline	O

The	O
main	O
clinical	O
features	O
of	O
the	O
study	O
population	O
(	O
n	O
=	O
2	O
,	O
656	O
)	O
at	O
baseline	O
,	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

Overall	O
,	O
the	O
mean	O
age	O
was	O
44	O
±	O
14	O
years	O
,	O
56	O
%	O
of	O
patients	O
were	O
males	O
and	O
the	O
mean	O
duration	O
of	O
diabetes	B-DS
was	O
17	O
±	O
12	O
years	O
.	O

The	O
average	O
BMI	O
was	O
24	O
.	O
4	O
±	O
3	O
.	O
4	O
Kg	O
/	O
m2	O
,	O
indicating	O
that	O
the	O
majority	O
of	O
patients	O
had	O
normal	O
body	O
weight	O
.	O

The	O
glycemic	O
control	O
was	O
rather	O
unfair	O
,	O
mean	O
values	O
of	O
HbA1c	O
being	O
7	O
.	O
7	O
%	O
(	O
60	O
.	O
66	O
mmol	O
/	O
mol	O
),	O
with	O
about	O
70	O
%	O
of	O
patients	O
showing	O
HbA1c	O
values	O
above	O
7	O
%	O
(	O
53	O
.	O
0	O
mmol	O
/	O
mol	O
).	O

On	O
the	O
contrary	O
,	O
lipids	O
and	O
BP	O
control	O
were	O
on	O
average	O
fairly	O
good	O
,	O
with	O
mean	O
values	O
of	O
low	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
c	O
)	O
and	O
BP	O
of	O
110	O
mg	O
/	O
dL	O
and	O
125	O
/	O
76	O
mmHg	O
,	O
respectively	O
(	O
Table	O
1	O
).	O

Baseline	O
eGFR	O
was	O
90	O
±	O
16	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
.	O

Twenty	O
percent	O
of	O
patients	O
were	O
receiving	O
antihypertensive	O
treatment	O
(	O
with	O
a	O
mean	O
of	O
1	O
.	O
6	O
drugs	O
per	O
patient	O
),	O
and	O
18	O
.	O
2	O
%	O
were	O
taking	O
an	O
ACE	B-GP
-	O
I	O
or	O
an	O
ARB	O
.	O

Retinopathy	B-DS
,	O
either	O
background	O
(	O
BG	O
)	O
or	O
proliferative	O
(	O
PR	O
),	O
was	O
more	O
frequent	O
among	O
patients	O
with	O
CKD	B-DS
and	O
with	O
each	O
of	O
its	O
components	O
,	O
particularly	O
among	O
patients	O
with	O
albuminuria	O
(	O
Table	O
1	O
).	O
Table	O
1Baseline	O
clinical	O
characteristics	O
of	O
whole	O
population	O
and	O
divided	O
by	O
the	O
occurrence	O
of	O
5	O
-	O
year	O
renal	O
outcome	O
among	O
2	O
,	O
656	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
.	O
AllCKDpeGFR	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2pAlbuminuriapPatientsNoYesNoYesNoYesn	O
=	O
2656n	O
=	O
2097n	O
=	O
559n	O
=	O
2541n	O
=	O
115n	O
=	O
2179n	O
=	O
477Male	O
sex1487	O
(	O
56	O
.	O
0	O
%)	O
1178	O
(	O
56	O
.	O
2	O
%)	O
309	O
(	O
55	O
.	O
3	O
%)	O
0	O
.	O
2201437	O
(	O
56	O
.	O
6	O
%)	O
50	O
(	O
43	O
.	O
5	O
%)	O
0	O
.	O
9791213	O
(	O
55	O
.	O
7	O
%)	O
274	O
(	O
57	O
.	O
4	O
%)	O
0	O
.	O
158Age	O
(	O
years	O
)	O
44	O
±	O
1443	O
±	O
1348	O
±	O
15	O
<	O
0	O
.	O
00143	O
±	O
1360	O
±	O
13	O
<	O
0	O
.	O
00143	O
±	O
1346	O
±	O
150	O
.	O
024Known	O
duration	O
of	O
diabetes	B-DS
(	O
years	O
)	O
17	O
±	O
1216	O
±	O
1119	O
±	O
12	O
<	O
0	O
.	O
00116	O
±	O
1123	O
±	O
130	O
.	O
01316	O
±	O
1119	O
±	O
12	O
<	O
0	O
.	O
001BMI	O
(	O
Kg	O
/	O
m2	O
)	O
24	O
.	O
4	O
±	O
3	O
.	O
424	O
.	O
3	O
±	O
3	O
.	O
324	O
.	O
6	O
±	O
3	O
.	O
70	O
.	O
29524	O
.	O
3	O
±	O
3	O
.	O
325	O
.	O
3	O
±	O
3	O
.	O
90	O
.	O
07124	O
.	O
3	O
±	O
3	O
.	O
324	O
.	O
5	O
±	O
3	O
.	O
80	O
.	O
376Serum	O
creatinine	O
(	O
mg	O
/	O
dL	O
)	O
0	O
.	O
84	O
±	O
0	O
.	O
160	O
.	O
84	O
±	O
0	O
.	O
160	O
.	O
85	O
±	O
0	O
.	O
170	O
.	O
3790	O
.	O
84	O
±	O
0	O
.	O
160	O
.	O
92	O
±	O
0	O
.	O
17	O
<	O
0	O
.	O
0010	O
.	O
84	O
±	O
0	O
.	O
160	O
.	O
84	O
±	O
0	O
.	O
170	O
.	O
351eGFR	O
(	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
)	O
99	O
±	O
16100	O
±	O
1695	O
±	O
18	O
<	O
0	O
.	O
001100	O
±	O
1678	O
±	O
14	O
<	O
0	O
.	O
00199	O
±	O
1698	O
±	O
170	O
.	O
611Serum	O
uric	O
acid	O
(	O
mg	O
/	O
dL	O
)	O
3	O
.	O
8	O
±	O
2	O
.	O
23	O
.	O
8	O
±	O
2	O
.	O
43	O
.	O
9	O
±	O
1	O
.	O
20	O
.	O
8903	O
.	O
8	O
±	O
2	O
.	O
24	O
.	O
0	O
±	O
1	O
.	O
40	O
.	O
9553	O
.	O
8	O
±	O
2	O
.	O
33	O
.	O
9	O
±	O
1	O
.	O
20	O
.	O
691SUA	O
in	O
the	O
top	O
gender	O
-	O
specific	O
quintile275	O
(	O
18	O
.	O
8	O
%)	O
204	O
(	O
17	O
.	O
7	O
%)	O
71	O
(	O
22	O
.	O
8	O
%)	O
0	O
.	O
521253	O
(	O
18	O
.	O
1	O
%)	O
22	O
(	O
32	O
.	O
4	O
%)	O
0	O
.	O
494216	O
(	O
18	O
.	O
0	O
%)	O
59	O
(	O
22	O
.	O
5	O
%)	O
0	O
.	O
302HbA1c	O
(%)	O
(	O
mmol	O
/	O
mol	O
)	O
7	O
.	O
7	O
±	O
1	O
.	O
3	O
(	O
60	O
±	O
9	O
)	O
7	O
.	O
6	O
±	O
1	O
.	O
3	O
(	O
59	O
±	O
9	O
)	O
7	O
.	O
9	O
±	O
1	O
.	O
4	O
(	O
63	O
±	O
8	O
)<	O
0	O
.	O
0017	O
.	O
6	O
±	O
1	O
.	O
3	O
(	O
59	O
±	O
9	O
)	O
8	O
.	O
1	O
±	O
1	O
.	O
5	O
(	O
65	O
±	O
7	O
)	O
0	O
.	O
0237	O
.	O
6	O
±	O
1	O
.	O
3	O
(	O
59	O
±	O
9	O
)	O
7	O
.	O
9	O
±	O
1	O
.	O
5	O
(	O
63	O
±	O
7	O
)<	O
0	O
.	O
001HbA1c	O
≥	O
7	O
%	O
(≥	O
53	O
mmol	O
/	O
mol	O
)	O
1843	O
(	O
69	O
.	O
4	O
%)	O
1433	O
(	O
68	O
.	O
3	O
%)	O
410	O
(	O
73	O
.	O
3	O
%)	O
0	O
.	O
1871754	O
(	O
69	O
.	O
0	O
%)	O
89	O
(	O
77	O
.	O
4	O
%)	O
0	O
.	O
5501495	O
(	O
68	O
.	O
6	O
%)	O
348	O
(	O
73	O
.	O
0	O
%)	O
0	O
.	O
189Total	O
cholesterol	O
(	O
mg	O
/	O
dL	O
)	O
189	O
±	O
34189	O
±	O
34189	O
±	O
350	O
.	O
248189	O
±	O
34194	O
±	O
350	O
.	O
591189	O
±	O
34188	O
±	O
350	O
.	O
309Triglycerides	O
(	O
mg	O
/	O
dL	O
)	O
84	O
±	O
5682	O
±	O
5493	O
±	O
640	O
.	O
00184	O
±	O
5791	O
±	O
520	O
.	O
70282	O
±	O
5494	O
±	O
66	O
<	O
0	O
.	O
001Triglycerides	O
≥	O
150	O
mg	O
/	O
dl191	O
(	O
7	O
.	O
2	O
%)	O
137	O
(	O
6	O
.	O
5	O
%)	O
54	O
(	O
9	O
.	O
7	O
%)	O
0	O
.	O
015181	O
(	O
7	O
.	O
1	O
%)	O
10	O
(	O
8	O
.	O
7	O
%)	O
0	O
.	O
867141	O
(	O
6	O
.	O
5	O
%)	O
50	O
(	O
10	O
.	O
5	O
%)	O
0	O
.	O
001HDL	O
(	O
mg	O
/	O
dL	O
)	O
62	O
±	O
1962	O
±	O
1962	O
±	O
180	O
.	O
10162	O
±	O
1965	O
±	O
180	O
.	O
43163	O
±	O
1961	O
±	O
180	O
.	O
059HDL	O
<	O
40	O
M	O
<	O
50	O
F	O
mg	O
/	O
dL294	O
(	O
11	O
.	O
1	O
%)	O
227	O
(	O
10	O
.	O
8	O
%)	O
67	O
(	O
12	O
.	O
0	O
%)	O
0	O
.	O
229282	O
(	O
11	O
.	O
1	O
%)	O
12	O
(	O
10	O
.	O
4	O
%)	O
0	O
.	O
896235	O
(	O
10	O
.	O
8	O
%)	O
59	O
(	O
12	O
.	O
4	O
%)	O
0	O
.	O
205LDL	O
(	O
mg	O
/	O
dL	O
)	O
110	O
±	O
31111	O
±	O
31108	O
±	O
310	O
.	O
064110	O
±	O
31111	O
±	O
310	O
.	O
949111	O
±	O
31108	O
±	O
310	O
.	O
058LDL	O
≥	O
100	O
mg	O
/	O
dL1650	O
(	O
62	O
.	O
1	O
%)	O
1320	O
(	O
62	O
.	O
9	O
%)	O
330	O
(	O
59	O
.	O
0	O
%)	O
0	O
.	O
0641583	O
(	O
62	O
.	O
3	O
%)	O
67	O
(	O
58	O
.	O
3	O
%)	O
0	O
.	O
4371367	O
(	O
62	O
.	O
7	O
%)	O
283	O
(	O
59	O
.	O
3	O
%)	O
0	O
.	O
099Systolic	O
BP	O
(	O
mmHg	O
)	O
125	O
±	O
17124	O
±	O
16129	O
±	O
19	O
<	O
0	O
.	O
001125	O
±	O
17137	O
±	O
18	O
<	O
0	O
.	O
001125	O
±	O
17128	O
±	O
180	O
.	O
001Diastolic	O
BP	O
(	O
mmHg	O
)	O
76	O
±	O
975	O
±	O
976	O
±	O
90	O
.	O
02476	O
±	O
978	O
±	O
90	O
.	O
03576	O
±	O
976	O
±	O
90	O
.	O
071Blood	O
Pressure	O
≥	O
140	O
/	O
85	O
mmHg779	O
(	O
29	O
.	O
3	O
%)	O
569	O
(	O
27	O
.	O
1	O
%)	O
210	O
(	O
37	O
.	O
6	O
%)<	O
0	O
.	O
001716	O
(	O
28	O
.	O
2	O
%)	O
63	O
(	O
54	O
.	O
8	O
%)<	O
0	O
.	O
001610	O
(	O
28	O
.	O
0	O
%)	O
169	O
(	O
35	O
.	O
4	O
%)	O
0	O
.	O
002	O
Retinopathy	B-DS
Non	O
-	O
proliferative495	O
(	O
18	O
.	O
6	O
%)	O
363	O
(	O
17	O
.	O
3	O
%)	O
132	O
(	O
23	O
.	O
6	O
%)	O
0	O
.	O
008468	O
(	O
18	O
.	O
4	O
%)	O
27	O
(	O
23	O
.	O
5	O
%)	O
0	O
.	O
347384	O
(	O
17	O
.	O
6	O
%)	O
111	O
(	O
23	O
.	O
3	O
%)	O
0	O
.	O
024	O
Proliferative152	O
(	O
5	O
.	O
7	O
%)	O
102	O
(	O
4	O
.	O
9	O
%)	O
50	O
(	O
8	O
.	O
9	O
%)<	O
0	O
.	O
001138	O
(	O
5	O
.	O
4	O
%)	O
14	O
(	O
12	O
.	O
2	O
%)	O
0	O
.	O
062110	O
(	O
5	O
.	O
0	O
%)	O
42	O
(	O
8	O
.	O
8	O
%)<	O
0	O
.	O
001Smokers357	O
(	O
26	O
.	O
2	O
%)	O
271	O
(	O
25	O
.	O
0	O
%)	O
86	O
(	O
31	O
.	O
0	O
%)	O
0	O
.	O
004349	O
(	O
26	O
.	O
8	O
%)	O
8	O
(	O
13	O
.	O
6	O
%)	O
0	O
.	O
207278	O
(	O
24	O
.	O
6	O
%)	O
79	O
(	O
34	O
.	O
2	O
%)	O
0	O
.	O
001Lipid	O
-	O
lowering	O
treatment416	O
(	O
15	O
.	O
7	O
%)	O
295	O
(	O
14	O
.	O
1	O
%)	O
121	O
(	O
21	O
.	O
6	O
%)	O
0	O
.	O
001385	O
(	O
15	O
.	O
2	O
%)	O
31	O
(	O
27	O
.	O
0	O
%)	O
0	O
.	O
168314	O
(	O
14	O
.	O
4	O
%)	O
102	O
(	O
21	O
.	O
4	O
%)	O
0	O
.	O
001Treatment	O
with	O
statins400	O
(	O
15	O
.	O
1	O
%)	O
281	O
(	O
13	O
.	O
4	O
%)	O
119	O
(	O
21	O
.	O
3	O
%)<	O
0	O
.	O
001369	O
(	O
14	O
.	O
5	O
%)	O
31	O
(	O
27	O
.	O
0	O
%)	O
0	O
.	O
073300	O
(	O
13	O
.	O
8	O
%)	O
100	O
(	O
21	O
.	O
0	O
%)<	O
0	O
.	O
001Treatment	O
with	O
fibrates9	O
(	O
0	O
.	O
3	O
%)	O
8	O
(	O
0	O
.	O
4	O
%)	O
1	O
(	O
0	O
.	O
2	O
%)	O
0	O
.	O
3669	O
(	O
0	O
.	O
4	O
%)	O
0	O
(	O
0	O
.	O
0	O
%)	O
1	O
.	O
0008	O
(	O
0	O
.	O
4	O
%)	O
1	O
(	O
0	O
.	O
2	O
%)	O
0	O
.	O
614Antihypertensive	O
treatment534	O
(	O
20	O
.	O
1	O
%)	O
357	O
(	O
17	O
.	O
0	O
%)	O
177	O
(	O
31	O
.	O
7	O
%)<	O
0	O
.	O
001480	O
(	O
18	O
.	O
9	O
%)	O
54	O
(	O
47	O
.	O
0	O
%)<	O
0	O
.	O
001390	O
(	O
17	O
.	O
9	O
%)	O
144	O
(	O
30	O
.	O
2	O
%)<	O
0	O
.	O
001Treatment	O
with	O
ACE	B-GP
-	O
Is	O
/	O
ARBs484	O
(	O
18	O
.	O
2	O
%)	O
324	O
(	O
15	O
.	O
5	O
%)	O
160	O
(	O
28	O
.	O
6	O
%)<	O
0	O
.	O
001434	O
(	O
17	O
.	O
1	O
%)	O
50	O
(	O
43	O
.	O
5	O
%)<	O
0	O
.	O
001355	O
(	O
16	O
.	O
3	O
%)	O
129	O
(	O
27	O
.	O
0	O
%)<	O
0	O
.	O
001Aspirin184	O
(	O
6	O
.	O
9	O
%)	O
128	O
(	O
6	O
.	O
1	O
%)	O
56	O
(	O
10	O
%)	O
0	O
.	O
024165	O
(	O
6	O
.	O
5	O
%)	O
19	O
(	O
16	O
.	O
5	O
%)	O
0	O
.	O
141140	O
(	O
6	O
.	O
4	O
%)	O
44	O
(	O
9	O
.	O
2	O
%)	O
0	O
.	O
026Insulin	O
pump162	O
(	O
6	O
.	O
1	O
%)	O
132	O
(	O
6	O
.	O
3	O
%)	O
30	O
(	O
5	O
.	O
4	O
%)	O
0	O
.	O
564155	O
(	O
6	O
.	O
1	O
%)	O
7	O
(	O
6	O
.	O
1	O
%)	O
0	O
.	O
420139	O
(	O
6	O
.	O
4	O
%)	O
23	O
(	O
4	O
.	O
8	O
%)	O
0	O
.	O
238Mean	O
±	O
SD	O
or	O
absolute	O
frequency	O
(	O
percentage	O
).	O

Serum	O
uric	O
acid	O
in	O
the	O
top	O
gender	O
-	O
specific	O
quintile	O
:	O
>	O
3	O
.	O
8	O
mg	O
/	O
dL	O
in	O
females	O
and	O
>	O
5	O
mg	O
/	O
dL	O
in	O
males	O
.	O

CKD	B-DS
,	O
chronic	B-DS
kidney	I-DS
disease	I-DS
;	O
eGFR	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
;	O
BMI	O
,	O
body	O
mass	O
index	O
;	O
SUA	O
,	O
serum	O
uric	O
acid	O
;	O
HbA1c	O
,	O
glycated	O
haemoglobin	B-GP
;	O
HDL	O
,	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
;	O
LDL	O
,	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
;	O
ACE	B-GP
-	O
Is	O
,	O
angiotensin	B-GP
converting	I-GP
enzyme	I-GP
-	O
inhibitors	O
;	O
ARBs	O
,	O
angiotensin	B-GP
II	I-GP
receptor	I-GP
antagonists	O
.	O

The	O
p	O
value	O
refers	O
to	O
the	O
association	O
between	O
patients	O
’	O
characteristics	O
and	O
outcome	O
at	O
mixed	O
logistic	O
regression	O
model	O
adjusting	O
for	O
baseline	O
eGFR	O
.	O

Patients	O
’	O
baseline	O
missing	O
data	O
:	O
BMI	O
in	O
131	O
(	O
4	O
.	O
9	O
%),	O
serum	O
uric	O
acid	O
in	O
1192	O
(	O
44	O
.	O
9	O
%),	O
total	O
cholesterol	O
in	O
21	O
(	O
0	O
.	O
8	O
%),	O
and	O
smoking	O
status	O
in	O
1294	O
(	O
48	O
.	O
7	O
%).	O

By	O
study	O
design	O
,	O
all	O
patients	O
had	O
normal	O
urine	O
albumin	B-GP
excretion	O
and	O
eGFR	O
≥	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
.	O

Five	O
-	O
year	O
follow	O
-	O
up	O
outcomes	O

Over	O
a	O
5	O
-	O
year	O
follow	O
-	O
up	O
period	O
,	O
a	O
total	O
of	O
21	O
.	O
0	O
%	O
of	O
patients	O
(	O
n	O
=	O
559	O
)	O
developed	O
CKD	B-DS
,	O
4	O
.	O
3	O
%	O
(	O
n	O
=	O
115	O
)	O
developed	O
reduced	O
eGFR	O
(	O
i	O
.	O
e	O
.	O
eGFR	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
)	O
and	O
18	O
.	O
0	O
%	O
(	O
n	O
=	O
477	O
)	O
albuminuria	O
(	O
444	O
=	O
microalbuminuria	O
and	O
33	O
=	O
macroalbuminuria	O
).	O

Only	O
a	O
minority	O
of	O
patients	O
(	O
n	O
=	O
33	O
,	O
1	O
.	O
2	O
%)	O
developed	O
both	O
features	O
of	O
chronic	B-DS
kidney	I-DS
disease	I-DS
(	O
CKD	B-DS
).	O

Baseline	O
clinical	O
features	O
of	O
patients	O
grouped	O
based	O
on	O
achieved	O
renal	O
outcome	O
within	O
the	O
study	O
period	O
are	O
also	O
reported	O
in	O
Table	O
1	O
.	O

On	O
average	O
,	O
patients	O
who	O
went	O
on	O
to	O
develop	O
CKD	B-DS
or	O
any	O
one	O
of	O
its	O
components	O
(	O
i	O
.	O
e	O
.	O
eGFR	O
<	O
60	O
ml	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
or	O
albuminuria	O
)	O
showed	O
a	O
worse	O
clinical	O
and	O
metabolic	O
profile	O
.	O

They	O
were	O
older	O
,	O
with	O
a	O
longer	O
history	O
of	O
diabetes	B-DS
and	O
poorer	O
glycemic	O
control	O
.	O

They	O
also	O
showed	O
higher	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
mean	O
values	O
and	O
higher	O
proportion	O
of	O
BP	O
values	O
above	O
140	O
/	O
85	O
mmHg	O
,	O
despite	O
a	O
greater	O
prevalence	O
of	O
antihypertensive	O
treatment	O
,	O
especially	O
with	O
an	O
ACE	B-GP
-	O
I	O
or	O
an	O
ARB	O
.	O

Higher	O
levels	O
of	O
triglycerides	O
were	O
associated	O
with	O
CKD	B-DS
and	O
,	O
particularly	O
,	O
with	O
the	O
development	O
of	O
albuminuria	O
(	O
Table	O
1	O
).	O

As	O
expected	O
,	O
patients	O
who	O
went	O
on	O
to	O
develop	O
reduced	O
eGFR	O
also	O
had	O
lower	O
eGFR	O
at	O
baseline	O
(	O
78	O
vs	O
.	O
100	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
,	O
patients	O
who	O
developed	O
reduced	O
eGFR	O
vs	O
.	O
patients	O
who	O
remained	O
with	O
stable	O
eGFR	O
,	O
respectively	O
)	O
(	O
Table	O
1	O
).	O

In	O
Table	O
2	O
we	O
report	O
risk	O
estimation	O
and	O
the	O
proportion	O
of	O
patients	O
developing	O
depressed	O
eGFR	O
and	O
/	O
or	O
albuminuria	O
stratified	O
by	O
age	O
and	O
duration	O
of	O
diabetes	B-DS
.	O
Table	O
25	O
-	O
year	O
incidence	O
of	O
CKD	B-DS
,	O
low	O
eGFR	O
and	O
albuminuria	O
by	O
age	O
and	O
duration	O
of	O
diabetes	B-DS
.	O
NAgeDurationCKDeGFR	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2Albuminuria	O
(	O
years	O
)(	O
years	O
)	O
IncidenceOdds	O
Ratio	O
(	O
95	O
%	O
CI	O
)	O
IncidenceOdds	O
Ratio	O
(	O
95	O
%	O
CI	O
)	O
IncidenceOdds	O
Ratio	O
(	O
95	O
%	O
CI	O
)	O
Age	O
18	O
–	O
30	O
years44025	O
±	O
310	O
±	O
780	O
(	O
18	O
.	O
2	O
%)—	O
1	O
(	O
0	O
.	O
2	O
%)—	O
80	O
(	O
18	O
.	O
2	O
%)—	O
31	O
–	O
40	O
years71135	O
±	O
314	O
±	O
9109	O
(	O
15	O
.	O
3	O
%)	O
0	O
.	O
71	O
(	O
0	O
.	O
51	O
–	O
0	O
.	O
99	O
)	O
p	O
=	O
0	O
.	O
0478	O
(	O
1	O
.	O
1	O
%)	O
4	O
.	O
64	O
(	O
0	O
.	O
58	O
–	O
37	O
.	O
40	O
)	O
p	O
=	O
0	O
.	O
149102	O
(	O
14	O
.	O
3	O
%)	O
0	O
.	O
65	O
(	O
0	O
.	O
46	O
–	O
0	O
.	O
92	O
)	O
p	O
=	O
0	O
.	O
014	O
41	O
–	O
50	O
years67245	O
±	O
317	O
±	O
11129	O
(	O
19	O
.	O
2	O
%)	O
1	O
.	O
18	O
(	O
0	O
.	O
88	O
–	O
1	O
.	O
59	O
)	O
p	O
=	O
0	O
.	O
26520	O
(	O
3	O
.	O
0	O
%)	O
2	O
.	O
53	O
(	O
1	O
.	O
10	O
–	O
5	O
.	O
82	O
)	O
p	O
=	O
0	O
.	O
029114	O
(	O
17	O
.	O
0	O
%)	O
1	O
.	O
08	O
(	O
0	O
.	O
79	O
–	O
1	O
.	O
47	O
)	O
p	O
=	O
0	O
.	O
629	O
>	O
50	O
years83360	O
±	O
723	O
±	O
13241	O
(	O
28	O
.	O
9	O
%)	O
1	O
.	O
68	O
(	O
1	O
.	O
29	O
–	O
2	O
.	O
20	O
)	O
p	O
<	O
0	O
.	O
00186	O
(	O
10	O
.	O
3	O
%)	O
3	O
.	O
59	O
(	O
2	O
.	O
14	O
–	O
6	O
.	O
01	O
)	O
p	O
<	O
0	O
.	O
001181	O
(	O
21	O
.	O
7	O
%)	O
1	O
.	O
34	O
(	O
1	O
.	O
00	O
–	O
1	O
.	O
78	O
)	O
p	O
=	O
0	O
.	O
047	O
Duration	O
of	O
diabetes	B-DS
≤	O
10	O
years93939	O
±	O
135	O
±	O
3158	O
(	O
16	O
.	O
8	O
%)—	O
26	O
(	O
2	O
.	O
8	O
%)—	O
139	O
(	O
14	O
.	O
8	O
%)—	O
11	O
–	O
20	O
years84142	O
±	O
1315	O
±	O
3171	O
(	O
20	O
.	O
3	O
%)	O
1	O
.	O
21	O
(	O
0	O
.	O
94	O
–	O
1	O
.	O
57	O
)	O
p	O
=	O
0	O
.	O
14731	O
(	O
3	O
.	O
7	O
%)	O
1	O
.	O
10	O
(	O
0	O
.	O
62	O
–	O
1	O
.	O
97	O
)	O
p	O
=	O
0	O
.	O
738150	O
(	O
17	O
.	O
8	O
%)	O
1	O
.	O
25	O
(	O
0	O
.	O
95	O
–	O
1	O
.	O
64	O
)	O
p	O
=	O
0	O
.	O
107	O
21	O
–	O
30	O
years51546	O
±	O
1225	O
±	O
3125	O
(	O
24	O
.	O
3	O
%)	O
1	O
.	O
20	O
(	O
0	O
.	O
91	O
–	O
1	O
.	O
59	O
)	O
p	O
=	O
0	O
.	O
20429	O
(	O
5	O
.	O
6	O
%)	O
1	O
.	O
18	O
(	O
0	O
.	O
67	O
–	O
2	O
.	O
09	O
)	O
p	O
=	O
0	O
.	O
566103	O
(	O
20	O
.	O
0	O
%)	O
1	O
.	O
19	O
(	O
0	O
.	O
88	O
–	O
1	O
.	O
60	O
)	O
p	O
=	O
0	O
.	O
250	O
>	O
30	O
years36156	O
±	O
1138	O
±	O
6105	O
(	O
29	O
.	O
1	O
%)	O
1	O
.	O
06	O
(	O
0	O
.	O
76	O
–	O
1	O
.	O
47	O
)	O
p	O
=	O
0	O
.	O
74429	O
(	O
8	O
.	O
0	O
%)	O
0	O
.	O
71	O
(	O
0	O
.	O
40	O
–	O
1	O
.	O
28	O
)	O
p	O
=	O
0	O
.	O
25885	O
(	O
23	O
.	O
5	O
%)	O
1	O
.	O
19	O
(	O
0	O
.	O
83	O
–	O
1	O
.	O
69	O
)	O
p	O
=	O
0	O
.	O
345Mean	O
±	O
SD	O
and	O
absolute	O
frequency	O
(	O
percentage	O
).	O

CI	O
=	O
Confidence	O
Interval	O
.	O

Odds	O
Ratio	O
with	O
95	O
%	O
confidence	O
interval	O
of	O
each	O
category	O
in	O
comparison	O
to	O
the	O
previous	O
one	O
.	O

Odds	O
Ratios	O
for	O
age	O
were	O
adjusted	O
for	O
duration	O
of	O
diabetes	B-DS
and	O
vice	O
versa	O
.	O

The	O
bold	O
value	O
refers	O
to	O
statistical	O
significance	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

The	O
relationship	O
between	O
the	O
onset	O
of	O
depressed	O
kidney	O
function	O
+	O
/−	O
albuminuria	O
and	O
its	O
traits	O
and	O
traditional	O
cardiovascular	O
risk	O
factors	O
was	O
further	O
investigated	O
by	O
multivariate	O
logistic	O
analysis	O
(	O
Table	O
3	O
).	O

Age	O
independently	O
affected	O
the	O
development	O
of	O
reduced	O
eGFR	O
,	O
with	O
a	O
10	O
-	O
year	O
risk	O
increase	O
of	O
95	O
%,	O
(	O
i	O
.	O
e	O
.	O
roughly	O
a	O
double	O
of	O
the	O
risk	O
),	O
while	O
duration	O
of	O
disease	O
independently	O
predicted	O
albuminuria	O
onset	O
with	O
a	O
10	O
-	O
year	O
risk	O
increase	O
of	O
1	O
.	O
5	O
%.	O

In	O
our	O
setting	O
gender	O
did	O
not	O
arise	O
as	O
an	O
independent	O
risk	O
factor	O
for	O
CKD	B-DS
or	O
its	O
traits	O
.	O
Table	O
3Multivariate	O
analysis	O
for	O
the	O
occurrence	O
of	O
5	O
-	O
year	O
renal	O
outcome	O
.	O
CKDpeGFR	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2pAlbuminuriapOdds	O
Ratio	O
(	O
95	O
%	O
CI	O
)	O
Odds	O
Ratio	O
(	O
95	O
%	O
CI	O
)	O
Odds	O
Ratio	O
(	O
95	O
%	O
CI	O
)	O
Male	O
sex1	O
.	O
01	O
(	O
0	O
.	O
81	O
–	O
1	O
.	O
27	O
)	O
0	O
.	O
9130	O
.	O
96	O
(	O
0	O
.	O
59	O
–	O
1	O
.	O
56	O
)	O
0	O
.	O
8731	O
.	O
04	O
(	O
0	O
.	O
82	O
–	O
1	O
.	O
32	O
)	O
0	O
.	O
760Age	O
(	O
by	O
10	O
years	O
)	O
1	O
.	O
07	O
(	O
0	O
.	O
96	O
–	O
1	O
.	O
18	O
)	O
0	O
.	O
203	O
1	O
.	O
95	O
(	O
1	O
.	O
57	O
–	O
2	O
.	O
43	O
)	O
<	O
0	O
.	O
001	O
0	O
.	O
93	O
(	O
0	O
.	O
84	O
–	O
1	O
.	O
04	O
)	O
0	O
.	O
227Known	O
duration	O
of	O
diabetes	B-DS
(	O
by	O
10	O
years	O
)	O
1	O
.	O
10	O
(	O
0	O
.	O
99	O
–	O
1	O
.	O
21	O
)	O
0	O
.	O
0810	O
.	O
98	O
(	O
0	O
.	O
81	O
–	O
1	O
.	O
18	O
)	O
0	O
.	O
807	O
1	O
.	O
15	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
28	O
)	O
0	O
.	O
014	O
BMI	O
(	O
Kg	O
/	O
m2	O
)	O
27	O
–	O
29	O
.	O
90	O
.	O
87	O
(	O
0	O
.	O
63	O
–	O
1	O
.	O
19	O
)	O
0	O
.	O
3690	O
.	O
85	O
(	O
0	O
.	O
45	O
–	O
1	O
.	O
62	O
)	O
0	O
.	O
6230	O
.	O
92	O
(	O
0	O
.	O
66	O
–	O
1	O
.	O
28	O
)	O
0	O
.	O
628	O
≥	O
301	O
.	O
02	O
(	O
0	O
.	O
65	O
–	O
1	O
.	O
59	O
)	O
0	O
.	O
9411	O
.	O
57	O
(	O
0	O
.	O
72	O
–	O
3	O
.	O
42	O
)	O
0	O
.	O
2521	O
.	O
04	O
(	O
0	O
.	O
65	O
–	O
1	O
.	O
66	O
)	O
0	O
.	O
862eGFR	O
below	O
90	O
by	O
10	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
1	O
.	O
48	O
(	O
1	O
.	O
26	O
–	O
1	O
.	O
73	O
)	O
<	O
0	O
.	O
001	O
2	O
.	O
92	O
(	O
2	O
.	O
28	O
–	O
3	O
.	O
74	O
)	O
<	O
0	O
.	O
001	O
1	O
.	O
08	O
(	O
0	O
.	O
91	O
–	O
1	O
.	O
29	O
)	O
0	O
.	O
389HbA1c	O
(%)	O
1	O
.	O
13	O
(	O
1	O
.	O
05	O
–	O
1	O
.	O
23	O
)	O
0	O
.	O
002	O
1	O
.	O
13	O
(	O
0	O
.	O
94	O
–	O
1	O
.	O
36	O
)	O
0	O
.	O
194	O
1	O
.	O
16	O
(	O
1	O
.	O
06	O
–	O
1	O
.	O
26	O
)	O
0	O
.	O
001	O
Triglycerides	O
(	O
by	O
20	O
mg	O
/	O
dL	O
)	O
1	O
.	O
04	O
(	O
1	O
.	O
01	O
–	O
1	O
.	O
08	O
)	O
0	O
.	O
021	O
1	O
.	O
00	O
(	O
0	O
.	O
92	O
–	O
1	O
.	O
09	O
)	O
0	O
.	O
955	O
1	O
.	O
05	O
(	O
1	O
.	O
02	O
–	O
1	O
.	O
09	O
)	O
0	O
.	O
005	O
HDL	O
(	O
by	O
10	O
mg	O
/	O
dL	O
)	O
0	O
.	O
95	O
(	O
0	O
.	O
89	O
–	O
1	O
.	O
02	O
)	O
0	O
.	O
1601	O
.	O
00	O
(	O
0	O
.	O
88	O
–	O
1	O
.	O
14	O
)	O
0	O
.	O
9940	O
.	O
97	O
(	O
0	O
.	O
90	O
–	O
1	O
.	O
04	O
)	O
0	O
.	O
321LDL	O
(	O
by	O
10	O
mg	O
/	O
dL	O
)	O
0	O
.	O
95	O
(	O
0	O
.	O
91	O
–	O
0	O
.	O
98	O
)	O
0	O
.	O
002	O
0	O
.	O
98	O
(	O
0	O
.	O
91	O
–	O
1	O
.	O
05	O
)	O
0	O
.	O
528	O
0	O
.	O
95	O
(	O
0	O
.	O
91	O
–	O
0	O
.	O
98	O
)	O
0	O
.	O
003	O
Systolic	O
BP	O
(	O
by	O
10	O
mmHg	O
)	O
1	O
.	O
06	O
(	O
0	O
.	O
97	O
–	O
1	O
.	O
15	O
)	O
0	O
.	O
1761	O
.	O
07	O
(	O
0	O
.	O
91	O
–	O
1	O
.	O
25	O
)	O
0	O
.	O
4301	O
.	O
05	O
(	O
0	O
.	O
96	O
–	O
1	O
.	O
14	O
)	O
0	O
.	O
305Diastolic	O
BP	O
(	O
by	O
10	O
mmHg	O
)	O
1	O
.	O
00	O
(	O
0	O
.	O
87	O
–	O
1	O
.	O
16	O
)	O
0	O
.	O
9631	O
.	O
06	O
(	O
0	O
.	O
79	O
–	O
1	O
.	O
43	O
)	O
0	O
.	O
6921	O
.	O
01	O
(	O
0	O
.	O
87	O
–	O
1	O
.	O
18	O
)	O
0	O
.	O
900	O
Retinopathy	B-DS
Non	O
-	O
proliferative1	O
.	O
12	O
(	O
0	O
.	O
85	O
–	O
1	O
.	O
46	O
)	O
0	O
.	O
4260	O
.	O
95	O
(	O
0	O
.	O
55	O
–	O
1	O
.	O
65	O
)	O
0	O
.	O
8621	O
.	O
09	O
(	O
0	O
.	O
82	O
–	O
1	O
.	O
46	O
)	O
0	O
.	O
548	O
Proliferative	O
1	O
.	O
57	O
(	O
1	O
.	O
03	O
–	O
2	O
.	O
38	O
)	O
0	O
.	O
036	O
1	O
.	O
31	O
(	O
0	O
.	O
62	O
–	O
2	O
.	O
76	O
)	O
0	O
.	O
475	O
1	O
.	O
57	O
(	O
1	O
.	O
01	O
–	O
2	O
.	O
44	O
)	O
0	O
.	O
045	O
Lipid	O
-	O
lowering	O
treatment1	O
.	O
09	O
(	O
0	O
.	O
81	O
–	O
1	O
.	O
46	O
)	O
0	O
.	O
5670	O
.	O
81	O
(	O
0	O
.	O
47	O
–	O
1	O
.	O
40	O
)	O
0	O
.	O
4551	O
.	O
22	O
(	O
0	O
.	O
90	O
–	O
1	O
.	O
66	O
)	O
0	O
.	O
208Antihypertensive	O
treatment1	O
.	O
87	O
(	O
0	O
.	O
97	O
–	O
3	O
.	O
61	O
)	O
0	O
.	O
0611	O
.	O
21	O
(	O
0	O
.	O
37	O
–	O
4	O
.	O
00	O
)	O
0	O
.	O
753	O
2	O
.	O
28	O
(	O
1	O
.	O
15	O
–	O
4	O
.	O
51	O
)	O
0	O
.	O
018	O
Treatment	O
with	O
ACE	B-GP
-	O
Is	O
/	O
ARBs0	O
.	O
93	O
(	O
0	O
.	O
48	O
–	O
1	O
.	O
80	O
)	O
0	O
.	O
8221	O
.	O
20	O
(	O
0	O
.	O
36	O
–	O
4	O
.	O
01	O
)	O
0	O
.	O
7630	O
.	O
77	O
(	O
0	O
.	O
38	O
–	O
1	O
.	O
53	O
)	O
0	O
.	O
455Aspirin0	O
.	O
84	O
(	O
0	O
.	O
56	O
–	O
1	O
.	O
27	O
)	O
0	O
.	O
4160	O
.	O
75	O
(	O
0	O
.	O
38	O
–	O
1	O
.	O
47	O
)	O
0	O
.	O
3970	O
.	O
93	O
(	O
0	O
.	O
60	O
–	O
1	O
.	O
44	O
)	O
0	O
.	O
741Insulin	O
pump0	O
.	O
96	O
(	O
0	O
.	O
61	O
–	O
1	O
.	O
51	O
)	O
0	O
.	O
8462	O
.	O
45	O
(	O
0	O
.	O
99	O
–	O
6	O
.	O
02	O
)	O
0	O
.	O
0520	O
.	O
75	O
(	O
0	O
.	O
46	O
–	O
1	O
.	O
25	O
)	O
0	O
.	O
275	O
Complete	O
case	O
analysis	O
Serum	O
uric	O
acid	O
(	O
mg	O
/	O
dL	O
)	O
0	O
.	O
96	O
(	O
0	O
.	O
87	O
–	O
1	O
.	O
06	O
)	O
0	O
.	O
4170	O
.	O
98	O
(	O
0	O
.	O
85	O
–	O
1	O
.	O
14	O
)	O
0	O
.	O
8100	O
.	O
97	O
(	O
0	O
.	O
87	O
–	O
1	O
.	O
07	O
)	O
0	O
.	O
515Smokers	O
1	O
.	O
69	O
(	O
1	O
.	O
21	O
–	O
2	O
.	O
36	O
)	O
0	O
.	O
002	O
0	O
.	O
88	O
(	O
0	O
.	O
37	O
–	O
2	O
.	O
11	O
)	O
0	O
.	O
777	O
1	O
.	O
84	O
(	O
1	O
.	O
29	O
–	O
2	O
.	O
62	O
)	O
0	O
.	O
001	O
See	O
Table	O
1	O
legend	O
for	O
abbreviations	O
.	O

Effects	O
of	O
clinical	O
characteristics	O

Worse	O
glycemic	O
control	O
affected	O
the	O
onset	O
of	O
albuminuria	O
,	O
with	O
an	O
increased	O
risk	O
of	O
16	O
%	O
for	O
every	O
1	O
%	O
increase	O
in	O
HbA1c	O
,	O
but	O
it	O
does	O
not	O
appear	O
to	O
bear	O
clinical	O
relevance	O
with	O
regards	O
to	O
the	O
risk	O
of	O
developing	O
low	O
eGFR	O
.	O

The	O
presence	O
of	O
antihypertensive	O
treatment	O
was	O
strongly	O
and	O
directly	O
related	O
to	O
the	O
onset	O
of	O
albuminuria	O
but	O
not	O
eGFR	O
reduction	O
.	O

Among	O
patients	O
with	O
baseline	O
eGFR	O
values	O
between	O
90	O
and	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
,	O
the	O
risk	O
of	O
developing	O
CKD	B-DS
or	O
reduced	O
eGFR	O
was	O
increased	O
by	O
a	O
measure	O
of	O
48	O
to	O
192	O
%,	O
respectively	O
each	O
for	O
10	O
ml	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
eGFR	O
reduction	O
.	O

CKD	B-DS
and	O
albuminuria	O
,	O
but	O
not	O
reduced	O
eGFR	O
,	O
onset	O
were	O
also	O
independently	O
predicted	O
by	O
higher	O
levels	O
of	O
triglycerides	O
with	O
4	O
%	O
and	O
5	O
%	O
increases	O
risk	O
for	O
CKD	B-DS
and	O
albuminuria	O
respectively	O
,	O
each	O
20	O
mg	O
/	O
dl	O
of	O
serum	O
triglycerides	O
(	O
Table	O
3	O
).	O

Figure	O
1	O
shows	O
the	O
association	O
of	O
study	O
variables	O
(	O
categorical	O
traits	O
)	O
with	O
the	O
risk	O
of	O
having	O
CKD	B-DS
,	O
low	O
eGFR	O
or	O
albuminuria	O
.	O

In	O
particular	O
,	O
when	O
we	O
considered	O
HbA1c	O
value	O
as	O
a	O
categorical	O
variable	O
(	O
i	O
.	O
e	O
.	O
above	O
or	O
below	O
7	O
%),	O
the	O
above	O
mentioned	O
relationship	O
with	O
CKD	B-DS
and	O
its	O
components	O
was	O
no	O
longer	O
statistically	O
significant	O
.	O
Figure	O
1Association	O
of	O
baseline	O
characteristics	O
(	O
categorical	O
traits	O
)	O
with	O
the	O
risk	O
of	O
having	O
CKD	B-DS
,	O
eGFR	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
or	O
albuminuria	O
.	O

Data	O
are	O
expressed	O
as	O
odds	O
ratios	O
(	O
ORs	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CIs	O
).	O

The	O
cumulative	O
incidence	O
of	O
CKD	B-DS
,	O
reduced	O
eGFR	O
(	O
i	O
.	O
e	O
.,	O
eGFR	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
)	O
and	O
albuminuria	O
in	O
the	O
whole	O
population	O
or	O
divided	O
according	O
to	O
eGFR	O
values	O
>	O
90	O
or	O
<	O
90	O
and	O
>	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
is	O
reported	O
in	O
Fig	O
.	O
2	O
,	O
panels	O
A	O
,	O
B	O
,	O
C	O
,	O
D	O
.	O

As	O
expected	O
,	O
the	O
incidence	O
of	O
renal	O
outcomes	O
increased	O
progressively	O
over	O
the	O
5	O
-	O
year	O
follow	O
-	O
up	O
period	O
and	O
was	O
higher	O
among	O
patients	O
with	O
a	O
lower	O
eGFR	O
at	O
baseline	O
(	O
i	O
.	O
e	O
.,	O
60	O
–	O
90	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
).	O
Figure	O
2Proportion	O
by	O
year	O
of	O
patients	O
with	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
)	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
,	O
albuminuria	O
and	O
CKD	B-DS
at	O
the	O
5	O
-	O
year	O
post	O
baseline	O
assessments	O
(	O
Panel	O
A	O
).	O

Proportion	O
by	O
year	O
of	O
patients	O
with	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
)	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
,	O
at	O
the	O
5	O
-	O
year	O
post	O
baseline	O
assessments	O
according	O
to	O
baseline	O
eGFR	O
<	O
or	O
>	O
90	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
(	O
Panel	O
B	O
).	O

Proportion	O
by	O
year	O
of	O
patients	O
with	O
albuminuria	O
,	O
at	O
the	O
5	O
-	O
year	O
post	O
baseline	O
assessments	O
according	O
to	O
baseline	O
eGFR	O
<	O
or	O
>	O
90	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
(	O
Panel	O
C	O
).	O

Proportion	O
by	O
year	O
of	O
patients	O
with	O
CKD	B-DS
at	O
the	O
5	O
-	O
year	O
post	O
baseline	O
assessments	O
according	O
to	O
baseline	O
eGFR	O
<	O
or	O
>	O
90	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
(	O
Panel	O
D	O
).	O

Tree	O
analysis	O
models	O

Finally	O
,	O
by	O
applying	O
a	O
tree	O
analysis	O
model	O
we	O
identified	O
5	O
patient	O
subgroups	O
at	O
different	O
risk	O
for	O
developing	O
eGFR	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
with	O
the	O
strongest	O
variable	O
in	O
differentiating	O
the	O
risk	O
being	O
baseline	O
eGFR	O
value	O
.	O

In	O
fact	O
,	O
patients	O
with	O
baseline	O
eGFR	O
≥	O
75	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
,	O
younger	O
age	O
(	O
i	O
.	O
e	O
.	O
<	O
65	O
years	O
)	O
and	O
shorter	O
duration	O
of	O
diabetes	B-DS
(	O
i	O
.	O
e	O
.	O
<	O
28	O
years	O
)	O
showed	O
the	O
lowest	O
incidence	O
of	O
eGFR	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
.	O

When	O
this	O
subgroup	O
of	O
patients	O
is	O
considered	O
as	O
the	O
reference	O
class	O
(	O
class	O
5	O
),	O
the	O
incidence	O
of	O
low	O
eGFR	O
progressively	O
increases	O
moving	O
from	O
class	O
5	O
to	O
class	O
1	O
,	O
whose	O
patients	O
have	O
a	O
lower	O
eGFR	O
and	O
age	O
>	O
65years	O
(	O
Supplemental	O
Fig	O
.	O
2	O
and	O
Supplemental	O
Table	O
3	O
).	O

As	O
for	O
albuminuria	O
,	O
5	O
different	O
subgroups	O
were	O
identified	O
by	O
tree	O
analysis	O
model	O
.	O

The	O
strongest	O
variable	O
in	O
differentiating	O
the	O
risk	O
of	O
developing	O
albuminuria	O
was	O
the	O
presence	O
of	O
antihypertensive	O
treatment	O
.	O

In	O
detail	O
,	O
patients	O
without	O
antihypertensive	O
treatment	O
with	O
triglycerides	O
≤	O
85	O
/	O
dl	O
and	O
HbA1c	O
<	O
8	O
.	O
7	O
%	O
(	O
71	O
.	O
59	O
mmol	O
/	O
mol	O
)	O
had	O
the	O
lowest	O
incident	O
rate	O
of	O
albuminuria	O
(	O
12	O
.	O
7	O
%).	O

When	O
this	O
subgroup	O
of	O
patients	O
is	O
considered	O
as	O
the	O
reference	O
class	O
,	O
the	O
incidence	O
of	O
albuminuria	O
progressively	O
increases	O
from	O
class	O
5	O
to	O
class	O
1	O
(	O
i	O
.	O
e	O
.	O
rate	O
=	O
44	O
.	O
1	O
%),	O
whose	O
patients	O
were	O
on	O
antihypertensive	O
treatment	O
and	O
had	O
eGFR	O
<	O
80	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
.	O

(	O
Supplemental	O
Table	O
3	O
).	O

Discussion	O

This	O
is	O
the	O
first	O
survey	O
from	O
Italy	O
investigating	O
the	O
natural	O
history	O
of	O
kidney	B-DS
dysfunction	I-DS
in	O
a	O
large	O
sample	O
of	O
adult	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
,	O
providing	O
important	O
hints	O
regarding	O
clinical	O
risk	O
factors	O
which	O
predict	O
CKD	B-DS
and	O
its	O
traits	O
,	O
in	O
a	O
real	O
life	O
setting	O
.	O

Our	O
data	O
show	O
that	O
in	O
a	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
population	O
with	O
a	O
mean	O
age	O
of	O
44	O
years	O
and	O
duration	O
of	O
diabetes	B-DS
of	O
17	O
years	O
,	O
up	O
to	O
21	O
.	O
0	O
%	O
of	O
patients	O
(	O
n	O
=	O
559	O
)	O
developed	O
CKD	B-DS
(	O
i	O
.	O
e	O
.	O
eGFR	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
or	O
albuminuria	O
),	O
4	O
.	O
3	O
%	O
(	O
n	O
=	O
115	O
)	O
reduced	O
eGFR	O
(	O
i	O
.	O
e	O
.	O
eGFR	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
)	O
and	O
18	O
.	O
0	O
%	O
(	O
n	O
=	O
477	O
)	O
albuminuria	O
(	O
i	O
.	O
e	O
.	O
444	O
microalbuminuria	O
and	O
33	O
macroalbuminuria	O
),	O
over	O
a	O
5	O
-	O
year	O
follow	O
-	O
up	O
period	O
.	O

We	O
can	O
estimate	O
that	O
,	O
in	O
Italy	O
,	O
in	O
5	O
year	O
follow	O
-	O
up	O
at	O
least	O
about	O
one	O
out	O
of	O
five	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
patients	O
attending	O
diabetes	B-DS
centers	O
will	O
develop	O
CKD	B-DS
.	O

There	O
was	O
a	O
constant	O
and	O
progressively	O
greater	O
incidence	O
of	O
renal	O
events	O
during	O
the	O
study	O
period	O
with	O
an	O
average	O
yearly	O
rate	O
of	O
reduced	O
eGFR	O
or	O
albuminuria	O
onset	O
between	O
0	O
.	O
5	O
and	O
1	O
.	O
2	O
%	O
and	O
between	O
2	O
.	O
5	O
and	O
4	O
.	O
8	O
%,	O
respectively	O
.	O

It	O
is	O
worth	O
nothing	O
that	O
lower	O
baseline	O
eGFR	O
values	O
significantly	O
affected	O
the	O
rate	O
of	O
renal	B-DS
impairment	I-DS
more	O
than	O
albuminuria	O
onset	O
.	O

As	O
for	O
the	O
effect	O
of	O
age	O
and	O
duration	O
of	O
diabetes	B-DS
on	O
CKD	B-DS
development	O
,	O
it	O
appears	O
that	O
while	O
the	O
prevalence	O
of	O
CKD	B-DS
steadily	O
increases	O
along	O
with	O
age	O
and	O
duration	O
of	O
disease	O
,	O
the	O
risk	O
of	O
developing	O
CKD	B-DS
is	O
relatively	O
unaffected	O
by	O
duration	O
of	O
diabetes	B-DS
.	O

The	O
relative	O
constant	O
incidence	O
of	O
CKD	B-DS
with	O
increasing	O
disease	O
duration	O
could	O
be	O
due	O
to	O
a	O
number	O
of	O
confounding	O
factors	O
,	O
such	O
as	O
the	O
influence	O
of	O
genetic	O
predisposition	O
to	O
develop	O
renal	O
complication	O
as	O
well	O
as	O
a	O
selection	O
bias	O
due	O
to	O
premature	O
death	O
in	O
those	O
prone	O
to	O
develop	O
renal	B-DS
disease	I-DS
.	O

Overall	O
,	O
in	O
our	O
setting	O
,	O
more	O
patients	O
developed	O
albuminuria	O
than	O
reduced	O
eGFR	O
,	O
a	O
finding	O
in	O
line	O
with	O
previously	O
published	O
longitudinal13	O
and	O
cross	O
-	O
sectional	O
studies14	O
.	O

The	O
incidence	O
of	O
CKD	B-DS
we	O
report	O
here	O
is	O
in	O
accord	O
with	O
the	O
trend	O
in	O
prevalence	O
recently	O
reported	O
by	O
Murphy	O
et	O
al	O
.	O
in	O
the	O
NHANES	O
survey	O
and	O
significantly	O
higher	O
than	O
what	O
is	O
observed	O
in	O
the	O
general	O
population	O
making	O
diabetes	B-DS
mellitus	I-DS
,	O
both	O
type	O
1	O
and	O
type	O
2	O
,	O
in	O
its	O
own	O
right	O
a	O
remarkable	O
risk	O
factor	O
for	O
CKD15	O
.	O

The	O
cumulative	O
incidence	O
of	O
CKD	B-DS
traits	O
we	O
describe	O
here	O
,	O
namely	O
reduced	O
eGFR	O
and	O
albuminuria	O
,	O
is	O
similar	O
to	O
that	O
reported	O
by	O
DCCT	O
/	O
EDIC	O
study	O
.	O

In	O
the	O
DCCT	O
/	O
EDIC	O
study	O
6	O
%	O
of	O
patients	O
developed	O
low	O
eGFR	O
(	O
i	O
.	O
e	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
,	O
73	O
m2	O
),	O
16	O
%	O
microalbuminuria	O
,	O
9	O
%	O
macroalbuminuria	O
.	O

Although	O
our	O
study	O
had	O
a	O
relatively	O
short	O
follow	O
-	O
up	O
,	O
the	O
mean	O
age	O
of	O
our	O
study	O
population	O
and	O
the	O
long	O
duration	O
of	O
disease	O
at	O
baseline	O
of	O
patients	O
we	O
recruited	O
make	O
our	O
results	O
comparable	O
to	O
those	O
from	O
DCCCT	O
/	O
EDIC13	O
.	O

The	O
cumulative	O
incidence	O
of	O
CKD	B-DS
in	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
appears	O
to	O
be	O
decreasing	O
over	O
time	O
.	O

The	O
figure	O
we	O
describe	O
herein	O
is	O
substantially	O
lower	O
when	O
compared	O
to	O
data	O
from	O
earlier	O
epidemiological	O
studies	O
carried	O
out	O
in	O
the	O
80	O
s	O
which	O
suggested	O
that	O
up	O
to	O
45	O
%	O
of	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
patients	O
developed	O
macroalbuminuria16	O
.	O

The	O
significant	O
improvement	O
in	O
the	O
management	O
of	O
traditional	O
risk	O
factors	O
,	O
namely	O
glycaemia	O
,	O
BP	O
and	O
cholesterol	O
,	O
as	O
well	O
as	O
the	O
reduction	O
in	O
the	O
rate	O
of	O
cigarette	O
smoking	O
and	O
increased	O
use	O
of	O
renin	B-GP
-	O
angiotensin	B-GP
system	O
inhibitors	O
recorded	O
over	O
the	O
years	O
,	O
may	O
account	O
for	O
these	O
differences	O
.	O

Whereas	O
renal	B-DS
impairment	I-DS
and	O
albuminuria	O
in	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
shared	O
a	O
number	O
of	O
risk	O
factors	O
,	O
there	O
also	O
was	O
a	O
distinct	O
set	O
of	O
variables	O
,	O
which	O
predicted	O
one	O
but	O
not	O
the	O
other	O
.	O

These	O
results	O
support	O
the	O
concept	O
that	O
albuminuria	O
and	O
renal	B-DS
impairment	I-DS
may	O
not	O
necessarily	O
reflect	O
the	O
same	O
underlying	O
pathophysiological	O
mechanism	O
in	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
.	O

Notwithstanding	O
,	O
some	O
peculiarities	O
need	O
to	O
be	O
mentioned	O
.	O

First	O
of	O
all	O
,	O
in	O
our	O
setting	O
,	O
worse	O
glycemic	O
control	O
appears	O
to	O
play	O
a	O
significant	O
role	O
in	O
increasing	O
the	O
risk	O
of	O
developing	O
CKD	B-DS
,	O
with	O
some	O
specificity	O
.	O

In	O
fact	O
,	O
while	O
in	O
the	O
univariate	O
model	O
increased	O
HbA1c	O
associated	O
with	O
CKD	B-DS
risk	O
and	O
each	O
of	O
its	O
components	O
,	O
in	O
the	O
multivariate	O
model	O
we	O
found	O
a	O
13	O
%	O
greater	O
risk	O
for	O
CKD	B-DS
and	O
a	O
16	O
%	O
greater	O
risk	O
for	O
albuminuria	O
onset	O
for	O
each	O
1	O
%	O
increase	O
in	O
HbA1c	O
.	O

We	O
could	O
not	O
detect	O
any	O
significant	O
association	O
between	O
glycemic	O
control	O
and	O
reduced	O
eGFR	O
.	O

This	O
finding	O
clearly	O
supports	O
the	O
strong	O
role	O
of	O
glycemic	O
control	O
as	O
a	O
risk	O
factor	O
for	O
albuminuria	O
in	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
patients	O
with	O
a	O
minor	O
role	O
for	O
renal	B-DS
impairment	I-DS
.	O

A	O
weak	O
relationship	O
between	O
glucose	O
control	O
and	O
GFR	O
decline	O
has	O
also	O
been	O
reported	O
by	O
other	O
observational	O
and	O
intervention	O
studies	O
such	O
as	O
the	O
DCCT	O
study17	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
role	O
of	O
hyperglycemia	B-DS
as	O
an	O
established	O
risk	O
factor	O
for	O
albuminuria	O
onset	O
results	O
also	O
from	O
several	O
intervention	O
studies18	O
,	O
including	O
DCCT19	O
,	O
which	O
unquestionably	O
demonstrate	O
that	O
intensive	O
glucose	O
control	O
results	O
in	O
a	O
clinically	O
important	O
and	O
durable	O
reduction	O
in	O
the	O
risk	O
of	O
albuminuria	O
onset	O
the	O
role	O
of	O
glycemic	O
control	O
on	O
the	O
progression	O
of	O
kidney	B-DS
damage	I-DS
is	O
not	O
so	O
clear	O
.	O

Triglycerides	O
also	O
are	O
strongly	O
related	O
to	O
albuminuria	O
onset	O
but	O
appear	O
to	O
have	O
no	O
significant	O
effect	O
on	O
reduced	O
eGFR	O
.	O

This	O
finding	O
has	O
also	O
been	O
reported	O
by	O
Hadjadi	O
et	O
al	O
.	O
who	O
described	O
serum	O
triglycerides	O
as	O
a	O
predictive	O
factor	O
for	O
the	O
development	O
and	O
the	O
progression	O
of	O
renal	O
and	O
retinal	O
complications	O
in	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus20	O
.	O

Moreover	O
,	O
low	O
levels	O
of	O
triglycerides	O
were	O
associated	O
with	O
regression	O
of	O
microalbuminuria21	O
.	O

Patients	O
who	O
went	O
on	O
to	O
develop	O
CKD	B-DS
and	O
its	O
components	O
had	O
a	O
significantly	O
higher	O
baseline	O
systolic	O
BP	O
as	O
compared	O
to	O
those	O
who	O
remained	O
with	O
stable	O
kidney	O
function	O
.	O

However	O
,	O
in	O
our	O
study	O
,	O
the	O
deleterious	O
effect	O
of	O
blood	O
pressure	O
disappeared	O
in	O
the	O
multivariate	O
model	O
.	O

This	O
somewhat	O
unexpected	O
finding	O
could	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
optimal	O
BP	O
control	O
(	O
i	O
.	O
e	O
.	O
mean	O
BP	O
=	O
125	O
±	O
17	O
/	O
76	O
±	O
9	O
mmHg	O
)	O
recorded	O
in	O
our	O
study	O
patients	O
.	O

Nonetheless	O
,	O
the	O
presence	O
(	O
and	O
degree	O
)	O
of	O
antihypertensive	O
treatment	O
entails	O
a	O
more	O
than	O
two	O
-	O
fold	O
risk	O
of	O
albuminuria	O
onset	O
.	O

Antihypertensive	O
treatment	O
could	O
therefore	O
be	O
considered	O
as	O
a	O
proxy	O
of	O
arterial	O
hypertension	B-DS
,	O
which	O
can	O
be	O
the	O
real	O
driver	O
of	O
kidney	B-DS
damage	I-DS
onset	O
.	O

The	O
presence	O
of	O
retinopathy	B-DS
,	O
either	O
BR	O
or	O
PR	O
,	O
was	O
more	O
common	O
among	O
patients	O
who	O
developed	O
CKD	B-DS
.	O

After	O
fully	O
adjusted	O
analysis	O
,	O
PR	O
remained	O
strongly	O
associated	O
to	O
albuminuria	O
,	O
which	O
developed	O
fifty	O
-	O
seven	O
percent	O
more	O
often	O
in	O
patients	O
with	O
baseline	O
PR	O
as	O
compared	O
to	O
those	O
without	O
retinopathy	B-DS
.	O

This	O
association	O
suggests	O
common	O
pathogenetic	O
mechanisms	O
for	O
PR	O
and	O
albuminuria	O
.	O

In	O
contrast	O
with	O
results	O
of	O
previous	O
studies22	O
,	O
we	O
found	O
no	O
association	O
between	O
serum	O
uric	O
acid	O
(	O
SUA	O
)	O
levels	O
and	O
renal	O
outcomes	O
.	O

This	O
discrepancy	O
may	O
mainly	O
be	O
due	O
to	O
differences	O
in	O
the	O
characteristics	O
of	O
the	O
population	O
studied	O
,	O
such	O
as	O
age	O
and	O
duration	O
of	O
disease	O
,	O
duration	O
of	O
follow	O
up	O
or	O
difference	O
in	O
the	O
definition	O
of	O
outcomes	O
.	O

As	O
expected	O
,	O
smoking	O
was	O
associated	O
with	O
albuminuria	O
alone	O
while	O
we	O
found	O
no	O
association	O
between	O
reduced	O
eGFR	O
and	O
smoking	O
.	O

These	O
findings	O
is	O
in	O
line	O
with	O
the	O
hypothesis	O
proposed	O
by	O
Chuahirun	O
et	O
al	O
.,	O
who	O
found	O
that	O
the	O
effect	O
of	O
smoking	O
was	O
mediated	O
by	O
albuminuria	O
in	O
patients	O
with	O
type	B-DS
2	I-DS
diabetes23	I-DS
.	O

Finally	O
,	O
the	O
tree	O
analysis	O
allowed	O
us	O
to	O
investigate	O
also	O
the	O
interaction	O
between	O
the	O
many	O
clinical	O
variables	O
we	O
considered	O
and	O
their	O
hierarchical	O
impact	O
on	O
the	O
incidence	O
of	O
reduced	O
eGFR	O
or	O
albuminuria	O
.	O

Results	O
of	O
these	O
analyses	O
may	O
provide	O
useful	O
information	O
for	O
real	O
life	O
clinical	O
practice	O
.	O

In	O
fact	O
,	O
we	O
found	O
that	O
among	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
and	O
preserved	O
renal	O
function	O
,	O
those	O
with	O
ongoing	O
antihypertensive	O
treatment	O
and	O
eGFR	O
<	O
80	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
are	O
at	O
highest	O
risk	O
for	O
albuminuria	O
onset	O
while	O
those	O
with	O
baseline	O
eGFR	O
<	O
75	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
and	O
age	O
>	O
60	O
years	O
are	O
at	O
highest	O
risk	O
for	O
renal	B-DS
impairment	I-DS
.	O

Our	O
study	O
has	O
some	O
limitations	O
as	O
well	O
as	O
several	O
strengths	O
that	O
should	O
be	O
mentioned	O
.	O

Among	O
the	O
first	O
ones	O
,	O
we	O
must	O
acknowledge	O
that	O
the	O
duration	O
of	O
follow	O
-	O
up	O
is	O
relatively	O
short	O
,	O
although	O
the	O
mean	O
age	O
of	O
patients	O
(	O
i	O
.	O
e	O
.	O
44	O
years	O
)	O
and	O
long	O
duration	O
of	O
disease	O
(	O
i	O
.	O
e	O
.	O
17	O
years	O
)	O
allowed	O
us	O
to	O
record	O
a	O
significant	O
number	O
of	O
events	O
.	O

Second	O
,	O
laboratory	O
parameters	O
,	O
including	O
serum	O
creatinine	O
were	O
not	O
measured	O
in	O
a	O
single	O
,	O
centralized	O
laboratory	O
which	O
may	O
have	O
led	O
to	O
some	O
variability	O
,	O
especially	O
in	O
GFR	O
estimation	O
.	O

In	O
addition	O
,	O
information	O
on	O
albuminuria	O
has	O
been	O
gathered	O
only	O
as	O
a	O
categorical	O
trait	O
and	O
this	O
may	O
also	O
have	O
contributed	O
to	O
variability	O
in	O
the	O
outcome	O
measure	O
.	O

Moreover	O
,	O
data	O
regarding	O
the	O
entire	O
5	O
-	O
year	O
follow	O
-	O
up	O
period	O
were	O
available	O
for	O
most	O
but	O
not	O
all	O
patients	O
and	O
therefore	O
caution	O
should	O
be	O
taken	O
not	O
to	O
generalize	O
our	O
findings	O
,	O
as	O
mortality	O
from	O
competitive	O
risk	O
was	O
not	O
positively	O
collected	O
in	O
the	O
missing	O
subgroup	O
.	O

Baseline	O
clinical	O
features	O
of	O
the	O
subgroup	O
with	O
missing	O
values	O
,	O
however	O
,	O
were	O
similar	O
to	O
that	O
of	O
the	O
entire	O
cohort	O
.	O

Finally	O
,	O
we	O
did	O
not	O
screen	O
our	O
population	O
for	O
non	O
-	O
diabetic	O
diseases	O
predisposing	O
to	O
CKD	B-DS
development	O
or	O
for	O
the	O
use	O
of	O
nephrotoxic	O
agents	O
.	O

However	O
,	O
considering	O
the	O
large	O
number	O
of	O
patients	O
recruited	O
,	O
their	O
relative	O
young	O
age	O
,	O
the	O
periodic	O
visits	O
they	O
have	O
had	O
at	O
diabetes	B-DS
centers	O
and	O
the	O
extremely	O
low	O
incidence	O
of	O
non	O
-	O
diabetic	B-DS
kidney	I-DS
disease	I-DS
in	O
this	O
setting	O
,	O
we	O
do	O
not	O
believe	O
that	O
non	O
-	O
diabetic	O
diseases	O
or	O
nephrotoxic	O
agents	O
could	O
have	O
significantly	O
affected	O
our	O
results	O
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
should	O
mention	O
the	O
large	O
size	O
and	O
homogeneous	O
clinical	O
characteristics	O
of	O
study	O
sample	O
as	O
well	O
as	O
the	O
representative	O
geographical	O
distribution	O
of	O
the	O
recruiting	O
centers	O
,	O
which	O
certainly	O
contribute	O
to	O
a	O
good	O
representation	O
of	O
real	O
life	O
clinical	O
conditions	O
.	O

In	O
conclusion	O
,	O
our	O
5	O
-	O
year	O
retrospective	O
analysis	O
of	O
a	O
large	O
,	O
real	O
life	O
,	O
cohort	O
of	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
and	O
preserved	O
kidney	O
function	O
at	O
baseline	O
showed	O
a	O
21	O
.	O
0	O
%	O
cumulative	O
incidence	O
of	O
CKD	B-DS
,	O
with	O
nearly	O
4	O
%	O
of	O
patients	O
developing	O
renal	B-DS
impairment	I-DS
and	O
18	O
%	O
albuminuria	O
.	O

Our	O
results	O
also	O
indicate	O
that	O
i	O
.	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
and	O
unfavorable	O
CV	O
risk	O
profile	O
are	O
at	O
high	O
risk	O
of	O
developing	O
CKD	B-DS
,	O
ii	O
.	O
the	O
two	O
main	O
traits	O
of	O
kidney	B-DS
dysfunction	I-DS
(	O
i	O
.	O
e	O
.	O
reduced	O
eGFR	O
and	O
albuminuria	O
)	O
in	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
mellitus	I-DS
share	O
several	O
determinants	O
,	O
although	O
with	O
some	O
specificity	O
that	O
needs	O
to	O
be	O
taken	O
into	O
account	O
when	O
describing	O
the	O
risk	O
profile	O
of	O
our	O
patients	O
.	O

Methods	O

Study	O
participants	O
and	O
design	O

In	O
Italy	O
diabetes	B-DS
care	O
is	O
mainly	O
provided	O
by	O
a	O
public	O
network	O
of	O
about	O
700	O
diabetes	B-DS
clinics	O
where	O
a	O
team	O
of	O
specialists	O
provide	O
diagnostic	O
confirmation	O
,	O
prevention	O
and	O
treatment	O
for	O
diabetes	B-DS
and	O
its	O
complications	O
through	O
close	O
patients	O
follow	O
-	O
up	O
and	O
regular	O
check	O
-	O
ups24	O
,	O
25	O
.	O

In	O
the	O
present	O
report	O
we	O
analyzed	O
a	O
large	O
sample	O
of	O
patients	O
with	O
type	B-DS
1	I-DS
diabetes	I-DS
,	O
(	O
according	O
to	O
American	O
Diabetes	B-DS
Association	O
2003	O
criteria	O
)	O
followed	O
-	O
up	O
at	O
137	O
centers	O
among	O
those	O
participating	O
in	O
the	O
Italian	O
Association	O
of	O
Clinical	O
Diabetologists	O
(	O
Associazione	O
Medici	O
Diabetologi	O
,	O
AMD	O
)	O
initiative	O
.	O

The	O
analysis	O
was	O
performed	O
using	O
the	O
data	O
set	O
of	O
electronic	O
medical	O
records	O
collected	O
between	O
1st	O
January	O
,	O
2004	O
and	O
30th	O
June	O
,	O
2011	O
.	O

For	O
the	O
purpose	O
of	O
the	O
analysis	O
,	O
we	O
considered	O
only	O
patients	O
who	O
were	O
≥	O
18	O
years	O
old	O
and	O
with	O
a	O
follow	O
-	O
up	O
evaluation	O
within	O
60	O
±	O
6	O
months	O
complete	O
for	O
data	O
about	O
estimated	O
GFR	O
(	O
eGFR	O
)	O
and	O
albuminuria	O
.	O

Of	O
5	O
,	O
486	O
patients	O
identified	O
,	O
we	O
excluded	O
those	O
with	O
albuminuria	O
,	O
eGFR	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
or	O
a	O
previous	O
eGFR	O
value	O
discordant	O
(	O
i	O
.	O
e	O
.	O
<	O
60	O
mL	O
min	O
/	O
1	O
.	O
73	O
m2	O
)	O
or	O
those	O
with	O
missing	O
data	O
of	O
antidiabetic	O
treatment	O
.	O

Two	O
-	O
thousand	O
-	O
six	O
-	O
hundred	O
-	O
fifty	O
-	O
six	O
patients	O
from	O
118	O
clinics	O
constitute	O
the	O
study	O
population	O
(	O
Supplemental	O
Fig	O
.	O
1	O
).	O

The	O
centers	O
involved	O
in	O
the	O
study	O
are	O
homogeneously	O
distributed	O
throughout	O
the	O
country	O
.	O

Data	O
collection	O

As	O
already	O
reported	O
,	O
the	O
analysis	O
of	O
the	O
database	O
is	O
an	O
attempt	O
by	O
the	O
Italian	O
Association	O
of	O
AMD	O
initiative	O
to	O
identify	O
a	O
set	O
of	O
indicators	O
that	O
can	O
be	O
used	O
in	O
the	O
context	O
of	O
continuous	O
quality	O
improvement	O
.	O

Participating	O
centres	O
adopted	O
the	O
same	O
software	O
systems	O
for	O
everyday	O
management	O
of	O
outpatients	O
,	O
while	O
a	O
specially	O
developed	O
software	O
package	O
allowed	O
us	O
to	O
extract	O
the	O
information	O
we	O
intended	O
to	O
analyze	O
from	O
all	O
the	O
clinical	O
databases	O
(	O
AMD	O
Data	O
File	O
).	O

Moreover	O
,	O
data	O
from	O
all	O
participating	O
centers	O
were	O
collected	O
and	O
centrally	O
analyzed	O
anonymously24	O
,	O
25	O
.	O

Laboratory	O
methods	O

This	O
initiative	O
includes	O
measuring	O
and	O
monitoring	O
HbA1c	O
,	O
blood	O
pressure	O
(	O
BP	O
),	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
-	O
c	O
),	O
total	O
and	O
high	O
density	O
lipoprotein	O
cholesterol	O
(	O
HDL	O
-	O
c	O
)	O
and	O
triglycerides	O
.	O

The	O
use	O
of	O
specific	O
classes	O
of	O
drugs	O
(	O
insulin	B-GP
,	O
statins	O
and	O
two	O
or	O
more	O
anti	O
-	O
hypertensive	O
agents	O
)	O
was	O
also	O
evaluated	O
.	O

Since	O
normal	O
ranges	O
for	O
HbA1c	O
varied	O
among	O
centers	O
,	O
the	O
percentage	O
change	O
with	O
respect	O
to	O
the	O
upper	O
normal	O
value	O
(	O
measured	O
value	O
⁄	O
upper	O
normal	O
limit	O
)	O
was	O
estimated	O
and	O
multiplied	O
by	O
6	O
.	O
0	O
in	O
order	O
to	O
allow	O
comparisons	O
among	O
the	O
centers	O
.	O

Kidney	O
function	O
was	O
assessed	O
by	O
serum	O
creatinine	O
and	O
urinary	O
albumin	B-GP
excretion	O
measurements	O
.	O

GFR	O
was	O
estimated	O
for	O
each	O
patient	O
using	O
a	O
standardized	O
serum	O
creatinine	O
assay	O
and	O
the	O
Chronic	B-DS
Kidney	I-DS
Disease	I-DS
Epidemiology	O
Collaboration	O
formula26	O
.	O

Increased	O
UAE	O
was	O
diagnosed	O
as	O
:	O
i	O
.	O
microalbuminuria	O
if	O
urinary	O
albumin	B-GP
concentration	O
was	O
>	O
30	O
and	O
≤	O
300	O
mg	O
/	O
l	O
,	O
or	O
if	O
UAE	O
rate	O
was	O
>	O
20	O
and	O
≤	O
200	O
μg	O
/	O
min	O
,	O
or	O
if	O
urinary	O
albumin	B-GP
-	O
to	O
-	O
creatinine	O
ratio	O
(	O
ACR	O
)	O
was	O
>	O
2	O
.	O
5	O
mg	O
/	O
mmol	O
in	O
men	O
and	O
>	O
3	O
.	O
5	O
mg	O
/	O
mmol	O
in	O
women	O
and	O
≤	O
30	O
mg	O
/	O
mmol	O
in	O
both	O
gender	O
;	O
ii	O
.	O
macroalbuminuria	O
if	O
urinary	O
albumin	B-GP
concentration	O
was	O
>	O
300	O
mg	O
/	O
l	O
,	O
or	O
if	O
UAE	O
rate	O
was	O
>	O
200	O
μg	O
/	O
min	O
,	O
or	O
if	O
ACR	O
was	O
>	O
30	O
mg	O
/	O
mmol	O
in	O
both	O
gender	O
.	O

Albuminuria	O
indicates	O
patients	O
with	O
either	O
micro	O
or	O
macroalbuminuria	O
.	O

Measurements	O

At	O
each	O
participating	O
centre	O
all	O
patients	O
underwent	O
physical	O
examination	O
and	O
BP	O
measurements	O
according	O
a	O
standardized	O
protocol	O
.	O

BP	O
was	O
measured	O
with	O
the	O
patient	O
in	O
the	O
sitting	O
position	O
after	O
a	O
5	O
-	O
minute	O
rest	O
,	O
with	O
a	O
mercury	O
sphygmomanometer	O
.	O

Systolic	O
BP	O
and	O
diastolic	O
BP	O
were	O
read	O
to	O
the	O
nearest	O
2	O
mmHg	O
.	O

Disappearance	O
of	O
Korotkoff	O
sounds	O
(	O
phase	O
V	O
)	O
was	O
the	O
criterion	O
for	O
diastolic	O
BP	O
.	O

Three	O
measurements	O
were	O
taken	O
at	O
2	O
-	O
minute	O
intervals	O
and	O
the	O
average	O
value	O
was	O
used	O
to	O
define	O
clinical	O
systolic	O
BP	O
and	O
diastolic	O
BP	O
.	O

CKD	B-DS
was	O
defined	O
as	O
diabetes	B-DS
with	O
albuminuria	O
or	O
low	O
eGFR	O
(	O
i	O
.	O
e	O
.	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
)	O
or	O
both	O
.	O

Information	O
on	O
the	O
presence	O
of	O
diabetic	B-DS
retinopathy	I-DS
,	O
BR	O
or	O
PR	O
,	O
was	O
also	O
available	O
.	O

The	O
outcomes	O
were	O
i	O
.	O

CKD	B-DS
(	O
i	O
.	O
e	O
.	O
eGFR	O
less	O
than	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
and	O
/	O
or	O
albuminuria	O
),	O
ii	O
.	O

eGFR	O
less	O
than	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
and	O
iii	O
.	O

Albuminuria	O
.	O

Occurrence	O
of	O
pre	O
specified	O
endpoints	O
was	O
evaluated	O
on	O
a	O
yearly	O
basis	O
over	O
the	O
5	O
-	O
year	O
study	O
period	O
.	O

Patients	O
were	O
considered	O
to	O
have	O
reached	O
the	O
study	O
endpoints	O
if	O
,	O
at	O
any	O
time	O
during	O
the	O
study	O
period	O
,	O
they	O
met	O
the	O
above	O
indicated	O
criteria	O
.	O

Approval	O

In	O
the	O
AMD	O
database	O
,	O
data	O
can	O
be	O
linked	O
together	O
by	O
a	O
unique	O
anonymous	O
identifier	O
that	O
is	O
encrypted	O
to	O
protect	O
patients	O
’	O
privacy	O
.	O

Because	O
this	O
automated	O
system	O
precludes	O
identification	O
of	O
individual	O
patients	O
,	O
according	O
to	O
the	O
Italian	O
law	O
ethical	O
committee	O
approval	O
and	O
informed	O
consent	O
were	O
not	O
required	O
.	O

The	O
results	O
were	O
internally	O
approved	O
by	O
the	O
AMD	O
ANNALS	O
Scientific	O
Committee	O
.	O

Statistical	O
analysis	O

Data	O
are	O
given	O
as	O
mean	O
values	O
±	O
standard	O
deviation	O
(	O
SD	O
);	O
categorical	O
variables	O
are	O
described	O
as	O
frequencies	O
and	O
percentages	O
.	O

The	O
analysis	O
was	O
aimed	O
to	O
evaluate	O
the	O
associations	O
between	O
baseline	O
characteristics	O
with	O
renal	O
outcomes	O
during	O
the	O
study	O
period	O
.	O

A	O
mixed	O
logistic	O
regression	O
model	O
with	O
diabetes	B-DS
clinics	O
fitted	O
as	O
random	O
effect	O
was	O
used	O
for	O
each	O
renal	O
outcome	O
to	O
estimate	O
odds	O
ratios	O
(	O
ORs	O
)	O
with	O
their	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
).	O

Multivariate	O
models	O
over	O
the	O
entire	O
population	O
were	O
fitted	O
including	O
a	O
missing	O
indicator	O
variable	O
for	O
patients	O
without	O
BMI	O
value	O
.	O

Multivariate	O
models	O
including	O
serum	O
uric	O
acid	O
and	O
smoking	O
status	O
were	O
performed	O
separately	O
as	O
complete	O
-	O
case	O
analysis	O
for	O
patients	O
with	O
all	O
data	O
available	O
(	O
1464	O
and	O
1362	O
patients	O
,	O
respectively	O
).	O

To	O
derive	O
a	O
hierarchical	O
tree	O
of	O
event	O
risk	O
,	O
a	O
logistic	O
model	O
for	O
renal	O
outcome	O
(	O
separately	O
for	O
eGFR	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
and	O
albuminuria	O
)	O
was	O
used	O
to	O
split	O
the	O
data	O
recursively	O
into	O
subgroups	O
selecting	O
the	O
variable	O
with	O
the	O
minimum	O
p	O
-	O
value	O
(	O
if	O
significant	O
<	O
0	O
.	O
05	O
).	O

Continuous	O
variables	O
were	O
analyzed	O
for	O
all	O
values	O
from	O
the	O
5th	O
to	O
95th	O
percentile	O
selecting	O
the	O
cut	O
-	O
point	O
with	O
the	O
lowest	O
p	O
-	O
value	O
.	O

The	O
tree	O
-	O
building	O
process	O
was	O
stopped	O
after	O
3	O
iterations	O
to	O
obtain	O
no	O
more	O
than	O
8	O
nodes	O
.	O

The	O
analyses	O
were	O
made	O
using	O
STATA	O
software	O
,	O
Version	O
14	O
(	O
StataCorp	O
,	O
College	O
Station	O
,	O
Texas	O
).	O

P	O
values	O
of	O
<	O
0	O
.	O
05	O
were	O
considered	O
statistically	O
significant	O
.	O

Electronic	O
supplementary	O
material	O

Supplementary	O
info	O

A	O
correction	O
to	O
this	O
article	O
is	O
available	O
online	O
at	O
https	O
://	O
doi	O
.	O
org	O
/	O
10	O
.	O
1038	O
/	O
s41598	O
-	O
018	O
-	O
23163	O
-	O
2	O
.	O

Electronic	O
supplementary	O
material	O

Supplementary	O
information	O
accompanies	O
this	O
paper	O
at	O
doi	O
:	O
10	O
.	O
1038	O
/	O
s41598	O
-	O
017	O
-	O
03551	O
-	O
w	O

Publisher	O
'	O
s	O
note	O
:	O
Springer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O

